PIB TrackerA Supreme Court order of January becomes an executive advisory in September
The Health Ministry told States that stem cell therapy is standard care only for indications on its approved list, and that any use in autism stays inside approved clinical trials. The authority is a judgment, not a new rule.
What happened
- The Ministry of Health and Family Welfare issued an advisory dated 16 September 2026 to all States and UTs that have adopted the Clinical Establishments (Registration and Regulation) Act, 2010.
- It was issued in view of the Supreme Court judgment of 30 January 2026 in Yash Charitable Trust and Ors. v. Union of India and Ors., W.P. (C) No. 369 of 2022, 2026 INSC 96.
- Stem cell therapy is to be permitted as standard care only for indications on the Ministry-approved list; use in Autism Spectrum Disorder is confined to duly approved clinical trials.
- The governing document is the National Guidelines for Stem Cell Research, 2017, issued jointly by ICMR and the Department of Biotechnology.
- Para 151(xiii) attaches consequences: professional misconduct under Regulation 7.22, IMC Regulations 2002, and Sections 32 and 40 of the Clinical Establishments Act - cancellation of registration and penalty.
For Prelims
- Yash Charitable Trust v. Union of India: W.P. (C) No. 369 of 2022, decided 30 January 2026, cited as 2026 INSC 96 - the judgment this advisory implements.
- Clinical Establishments Act, 2010: a central law that States must adopt; Section 32 provides for cancellation of registration and Section 40 for penalty.
- Regulation 7.22, IMC Regulations 2002: the professional-misconduct provision to which para 151(xiii) routes non-compliance by a registered medical practitioner.
- National Guidelines for Stem Cell Research, 2017: issued jointly by ICMR and DBT; it is the instrument confining autism stem cell use to approved trials.
- Standard care vs clinical trial: the advisory's central distinction - approved indications may be treated routinely; everything else, including ASD, only inside a trial with regulatory approval.
- NMC advisory, 5 September 2026: separately bars unauthorised administration, prescription, promotion or advertisement beyond approved indications.
- Enforcement tier: State and District Regulatory Authorities under the Clinical Establishments Act, and State Medical Councils for practitioner misconduct.
- Unproven stem cell intervention: the category the advisory names - not to be offered as routine, standard or commercial clinical services.
For UPSC: A compact illustration of how a constitutional court order becomes administrative practice through advisories to States rather than fresh legislation. Use it on judicial review and policy implementation, on regulation of medical practice in a federal health system, and on protecting vulnerable patients from unproven commercial treatment.
What it is NOT: The advisory does not publish the Ministry-approved list of indications, so the release does not say what stem cell therapy may lawfully treat - only what it may not. It names no clinic, gives no count of establishments offering unapproved stem cell therapy for autism, sets no deadline for State compliance and reports no action taken in the seven and a half months since the judgment. It also binds only those States that have adopted the Clinical Establishments Act, and does not say which States have not.
For Mains
Syllabus: GS2.6 · GS2.13 · Linkage L2
Anchor
The gap between a judgment and a practice is administrative, and it is measurable. The Supreme Court decided Yash Charitable Trust on 30 January 2026; the Health Ministry wrote to the States on 16 September 2026. Seven and a half months is the interval in which a right declared in Delhi reaches a clinic in a district.
Substantiation (data)
The advisory carries an unusually complete citation chain: W.P. (C) No. 369 of 2022, decided 30 January 2026 as 2026 INSC 96, with para 151(xiii) routing non-compliance to Regulation 7.22 of the IMC Regulations 2002 and Sections 32 and 40 of the Clinical Establishments Act, 2010. The NMC added its own advisory on 5 September 2026.
Exemplification
Autism is the specific case and the reason the litigation existed. Families pay for stem cell infusions marketed as treatment for a condition where no stem cell therapy is approved. The advisory confines any such use to a regulated trial, which converts a purchase into an enrolment with oversight.
Problematisation
The instrument is an advisory. It binds only States that have adopted the Clinical Establishments Act, it does not publish the approved list of indications it makes central, and it reports no enforcement in the intervening months. Regulation that names its penalties precisely but not its prohibited practitioners tends to change behaviour slowly.
Position
Health is a State subject and medical education and practice are regulated centrally, so an unproven therapy sits in the seam between the two. The Court's device was to attach consequences on both sides at once - the establishment through the Clinical Establishments Act, the doctor through the IMC Regulations - which is the design worth noting.
Conclusion
Cite this where an answer needs a current instance of judicial direction operationalised without new law. Nothing was enacted; an existing framework was restated with the Court's authority behind it, and the enforcement burden was pushed down to State and District Regulatory Authorities and State Medical Councils.
Deploys into: Judicial review and implementation of court orders · Regulation of medical practice in a federal system · Protection of vulnerable groups from unproven treatment · Statutory and regulatory bodies in health
Ministry of Health and Family Welfare · 2026-09-17 · PRID 2311179 · PIB source ↗